Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

BetterLife Pharma Inc

Healthcare US BETRF

0.0471USD
0.0041(9.53%)

Last update at 2026-06-03T18:26:00Z

Day Range

0.050.05
LowHigh

52 Week Range

0.030.09
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap8.09M
  • Volume85600
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.19145M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.02281M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Income before tax -3.62188M -2.89851M -9.37277M -11.99251M -36.35079M
Minority interest 0.10M 0.00948M 0.36M - -
Net income -3.52029M -2.88903M -9.01620M -12.15917M -36.35079M
Selling general administrative 4.30M 2.64M 6.56M 4.53M 7.56M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.00000M 0.00000M 0.02M 0.02M 0.34M
Ebit - - - -9.96962M -7.95442M
Ebitda - - -9.28716M -11.91573M -35.96788M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -4.72493M -3.20989M -9.25744M -9.96962M -7.95442M
Other operating expenses - - - - -
Interest expense 0.32M 0.05M 0.07M 0.06M 0.04M
Tax provision - 0.00000M 0.00000M 0.17M -
Interest income - - 0.00000M 0.00000M 0.00026M
Net interest income 0.44M -0.08495M -0.09109M -1.28287M -0.22204M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.17M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 4.72M 3.21M 9.26M 9.97M 7.95M
Cost of revenue - - - - -
Total other income expense net 0.66M 0.40M -0.02424M -0.74002M -28.17434M
Discontinued operations - - - - -
Net income from continuing ops -3.62188M -2.89851M -9.37277M -12.15917M -36.35079M
Net income applicable to common shares - - - -12.15917M -36.35079M
Preferred stock and other adjustments - - - - -
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Total assets 0.22M 0.32M 0.07M 1.16M 1.34M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.21M 0.25M - - -
Total liab 7.59M 8.02M 7.61M 5.04M 5.95M
Total stockholder equity -10.67753M -10.80852M -10.72822M -3.88086M -4.61226M
Deferred long term liab - - - - -
Other current liab 0.31M 0.00447M - 0.38M 0.18M
Common stock - - - 75.38M 63.67M
Capital stock 79.97M 78.46M 76.57M 75.38M 63.67M
Retained earnings -118.59600M -115.07571M -112.18668M -103.17048M -91.01131M
Other liab - - - 0.86M 0.13M
Good will - - - - -
Other assets - - - - -
Cash 0.00818M 0.04M 0.00831M 0.17M 0.15M
Cash and equivalents - - - - -
Total current liabilities 7.54M 6.83M 7.15M 4.14M 5.85M
Current deferred revenue - - - - -
Net debt 0.91M 0.29M 0.07M 0.14M 0.35M
Short term debt - - - - -
Short long term debt 0.87M - 0.08M 0.28M 0.50M
Short long term debt total - - - - -
Other stockholder equity - - - 23.91M 22.73M
Property plant equipment - - - 0.02M 0.04M
Total current assets 0.22M 0.32M 0.07M 1.14M 1.33M
Long term investments - - - - -
Net tangible assets - - - -3.88086M -4.61226M
Short term investments - - - - -
Net receivables 0.01M 0.04M 0.02M 0.32M 0.52M
Long term debt 0.05M 0.33M - 0.03M -
Inventory - - - - -
Accounts payable 4.50M 4.98M 5.44M 3.34M 4.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.02M 0.04M
Capital lease obligations 0.38M 1.14M 1.11M 1.08M -
Long term debt total - - - - -
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Investments - - 0.00000M 0.00000M -0.07155M
Change to liabilities - - 0.00000M -1.15759M -0.99393M
Total cashflows from investing activities - - - - -0.07155M
Net borrowings 1.22M 0.30M - -0.13000M 0.10M
Total cash from financing activities 1.99M 2.50M 1.34M 11.23M 4.09M
Change to operating activities - - - -0.50650M -0.20037M
Net income -3.52029M -2.88903M -9.01620M -12.15917M -36.35079M
Change in cash -0.02920M 0.03M -0.16521M 0.02M -3.12698M
Begin period cash flow 0.04M 0.00831M 0.17M 0.15M 3.28M
End period cash flow 0.00818M 0.04M 0.00831M 0.17M 0.15M
Total cash from operating activities -2.02175M -2.47241M -1.50351M -11.20282M -7.16488M
Issuance of capital stock 0.70M 2.20M 0.83M 11.44M 1.29M
Depreciation 0.00000M 0.00000M 0.02M 0.02M 0.34M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.18M -0.34990M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 0.19M 1.08M 2.61M
Change to netincome - - - 2.25M 30.39M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.75M 0.32M 3.43M -1.31640M -1.54419M
Stock based compensation 2.05M 0.50M 0.95M 1.23M 0.83M
Other non cash items -1.40106M -0.09060M 3.07M 0.97M 18.21M
Free cash flow -2.02175M -2.47241M -1.50351M -11.20282M -7.26150M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BETRF
BetterLife Pharma Inc		 0.0041 9.53% 0.05 - - - 13.65 -0.815
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

BetterLife Pharma Inc

1275 West 6th Avenue, Vancouver, BC, Canada, V6H 1A6

Key Executives

Name Title Year Born
Dr. Ahmad Doroudian Ph.D. Founder, CEO & Chairman 1960
Ms. Moira Ong C.A., CPA, CA, CFA Chief Financial Officer 1975
Dr. Hooshmand Sheshbaradaran Ph.D. Chief Operating Officer 1968
Mr. Scott Rudge Ph.D. Head of CMC NA
Anthony Calandra Ph.D. Head of Regulatory NA
Dr. Abdi Ghaffari Ph.D. Head of Preclinical & Toxicology NA
Dr. Hooshmand Sheshbaradaran Ph.D. Chief Operating Officer 1957
Dr. Stephen Sangha Corporate Development Advisor NA
Ms. Moira Ong C.A., CPA, CFA Chief Financial Officer 1975
Dr. Stephen Sangha Corporate Development Advisor & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.